THERAPEUTIC VACCINES, a new approach to ficht cancers
Urodelia has developed an autologous therapeutic vaccine combining proteins from tumor cells with hydroxyapatite. Based on the results obtained in animals, Urodelia is now entering a decisive phase: the development of its autologous therapeutic vaccine in human oncology.
Today Urodelia is on the threshold of a new stage of its development: the implementation of a program of clinical studies on its therapeutic vaccine to confirm in humans the first conclusions obtained in animals:
- Confirmation of the efficiency of its concept of an autologous therapeutic vaccine for humans OR human medicine
- Validation of the same total safety of the vaccine in humans as in animals